Ntla stock forecast following Q2 earnings beat

Following Q2 earnings beat, NTLA stock forecast revisions have tilted upward; EPS loss was narrower than consensus, raising confidence in capital efficiency through On a preliminary basis, lead drug Eylea and Eylea HD (higher dose of Eylea) recorded $6 billion in sales in 2024 in the United States. Sales for the fourth quarter amounted to $1.5 billion in the United States.  On a standalone basis, Eylea sales totaled $1.19 billion in the United States in the fourth quarter of 2024. Eylead HD’s net product sales were $305 million in the fourth quarter of 2024 in the United States. Multiple analysts have issued price targets for $NTLA recently. We have seen 13 analysts offer price targets for $NTLA in the last 6 months, with a median target of $26.0. NTLA stock forecast from multi-factor AI-driven models indicates a likely trading range of $35–$43 over the next quarter, aligning with sector benchmark trends despite inherent biotech uncertainty.